For health care professionals

Immune checkpoint inhibitor (ICI) therapy, which may now be an option for about half of U.S. patients with cancer, has transformed the treatment of many cancers. As the use of this type of immunotherapy increases, oncologists and other providers are being confronted with a rise in immune-related adverse events (irAEs). These events range from mild to severe and can jeopardize treatment success and patient’s well-being.

Nuclear medicine therapies, such as Lu-177 dotatate (Lutathera®), Lu-177 vipivotide tetraxetan, or Lu-177 PSMA (Pluvicto®) and radioiodine, are important tools for treating some types of cancer. Find out how Fred Hutch radiologists deliver nuclear medicine therapy and how to consult with specialists on your next case. 

In an ongoing effort to develop cancer therapies that provide a better quality of life, Fred Hutchinson Cancer Center physicians are spearheading the next generation of cancer treatments that transform radiation therapy into precision medicine. This innovative strategy uses different types of radiation, such as X-rays, protons and neutrons, to trigger an immune response and enhance the effectiveness of immunotherapy. 

For patients with gynecologic cancer, research shows that receiving treatment from a gynecologic oncologist right from the start improves patient outcomes. Does that mean every patient with gynecologic cancer needs to be treated full-time at a National Cancer Institute-designated cancer center, like the Fred Hutchinson Cancer Center? Not necessarily.